Monday, April 27, 2009

New TB vaccine candidate enters phase IIb proof-of-concept trial in South Africa

The Aeras Global TB Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd, Isis Innovation Ltd, the Wellcome Trust and the University of Cape Town (UCT) announce the start of a phase-IIb proof-of-concept clinical trial of a promising new TB vaccine developed at the University of Oxford called MVA85A/AERAS-485.

the details can be read here.

No comments: